Last reviewed · How we verify
Acaroid
Acaroid is a Biologic drug developed by Allergopharma GmbH & Co. KG. It is currently in Phase 3 development. Also known as: Specific Immunotherapy.
Acaroid is a specific immunotherapy used to treat rhinoconjunctivitis and respiratory hypersensitivity. It is administered subcutaneously in increasing doses up to 6000 TU.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Acaroid |
|---|---|
| Also known as | Specific Immunotherapy |
| Sponsor | Allergopharma GmbH & Co. KG |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma (PHASE3)
- Multicenter Trial of Immunotherapy With House Dust Mite Allergoid (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acaroid CI brief — competitive landscape report
- Acaroid updates RSS · CI watch RSS
- Allergopharma GmbH & Co. KG portfolio CI
Frequently asked questions about Acaroid
What is Acaroid?
Who makes Acaroid?
Is Acaroid also known as anything else?
What development phase is Acaroid in?
Related
- Manufacturer: Allergopharma GmbH & Co. KG — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Specific Immunotherapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing